The Situation

A biopharmaceutical company focused on commercializing treatments across more than ten rare disease areas sought a strategic intelligence partner to support long-term decision-making. The client needed visibility into early-stage competitor activity, evolving pipelines, and commercial moves in both U.S. and European markets.

The Solution

Sedulo launched a comprehensive monitoring and research engagement that expanded over four years. The program blended primary and secondary research methodologies to monitor 30 competitor assets and deliver tailored intelligence across the full clinical-to-commercial spectrum.

• Competitor Deep Dives: Conducted in-depth analyses of emerging and existing competitors across 10+ rare disease indications.
• Regulatory and Pipeline Tracking: Investigated timelines, filings, and development paths, including regional nuances such as EMA requirements.
• Primary Intelligence: Collected validated insights through direct interviews with KOLs, PIs, clinical staff, and executive leadership.
• Real-Time Monitoring: Delivered news alerts and clinical development updates based on investor calls, public disclosures, and internal confirmation.
• Conference Intelligence: Provided onsite and virtual coverage of key scientific meetings relevant to each disease area.
• Executive Reporting: Delivered executive-ready reports with synthesized insights, implications, and forward-looking recommendations.